$CLDX
Celldex Therapeutics, Inc.

2012 Q4 Form 10-Q Financial Statement

#000110465912073441 Filed on November 02, 2012

View on sec.gov

Income Statement

Concept 2012 Q4 2012 Q3 2011 Q4
Revenue $3.647M $3.113M $2.433M
YoY Change 49.9% 31.74% -93.55%
Cost Of Revenue $3.550M $3.010M $2.360M
YoY Change 50.42% 29.74% -65.29%
Gross Profit $100.0K $110.0K $80.00K
YoY Change 25.0% 120.0% -99.74%
Gross Profit Margin 2.74% 3.53% 3.29%
Selling, General & Admin $2.650M $2.840M $2.290M
YoY Change 15.72% 25.11% -9.49%
% of Gross Profit 2650.0% 2581.82% 2862.5%
Research & Development $13.75M $11.77M $9.820M
YoY Change 40.02% 36.94% 45.7%
% of Gross Profit 13750.0% 10699.09% 12275.0%
Depreciation & Amortization $720.0K $770.0K $840.0K
YoY Change -14.29% -36.89% -16.83%
% of Gross Profit 720.0% 700.0% 1050.0%
Operating Expenses $16.65M $11.77M $12.46M
YoY Change 33.63% 36.94% 27.14%
Operating Profit -$16.55M -$14.75M -$12.38M
YoY Change 33.68% 28.52% -158.62%
Interest Expense -$260.0K $381.0K -$350.0K
YoY Change -25.71% -13.01% -122.73%
% of Operating Profit
Other Income/Expense, Net $105.0K
YoY Change -27.08%
Pretax Income -$16.81M -$15.03M -$12.73M
YoY Change 32.05% 27.7% -156.18%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$16.81M -$15.03M -$12.73M
YoY Change 32.05% 27.7% -156.18%
Net Earnings / Revenue -460.93% -482.81% -523.22%
Basic Earnings Per Share
Diluted Earnings Per Share -$4.031M -$3.795M -$4.215M
COMMON SHARES
Basic Shares Outstanding 61.98M shares 59.29M shares 44.15M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2012 Q4 2012 Q3 2011 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $83.96M $77.62M $53.31M
YoY Change 57.49% 23.59% -12.75%
Cash & Equivalents $24.90M $23.19M $11.90M
Short-Term Investments $59.07M $54.43M $41.41M
Other Short-Term Assets $1.100M $1.200M $1.200M
YoY Change -8.33% -14.29% -20.0%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00 $200.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $85.11M $78.81M $54.68M
YoY Change 55.65% 22.41% -13.13%
LONG-TERM ASSETS
Property, Plant & Equipment $7.205M $7.566M $9.093M
YoY Change -20.76% -20.36% -16.05%
Goodwill $8.965M $8.965M $8.965M
YoY Change 0.0% 0.0%
Intangibles $23.83M $24.09M $24.92M
YoY Change -4.37% -7.13%
Long-Term Investments
YoY Change
Other Assets $424.0K $409.0K $329.0K
YoY Change 28.88% 36.33% -9.37%
Total Long-Term Assets $40.43M $41.03M $43.31M
YoY Change -6.66% -6.9% -7.84%
TOTAL ASSETS
Total Short-Term Assets $85.11M $78.81M $54.68M
Total Long-Term Assets $40.43M $41.03M $43.31M
Total Assets $125.5M $119.8M $97.99M
YoY Change 28.11% 10.5% -10.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $745.0K $1.281M $935.0K
YoY Change -20.32% 156.2% 0.43%
Accrued Expenses $10.96M $8.157M $7.008M
YoY Change 56.39% 35.95% 41.98%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.600M $5.300M $6.100M
YoY Change -8.2% 29.27% -54.81%
Total Short-Term Liabilities $17.69M $15.13M $14.30M
YoY Change 23.69% 40.39% -29.25%
LONG-TERM LIABILITIES
Long-Term Debt $5.700M $7.300M $9.000M
YoY Change -36.67% -33.64% 1.12%
Other Long-Term Liabilities $6.336M $6.365M $5.966M
YoY Change 6.2% 6.08% 6.71%
Total Long-Term Liabilities $6.336M $6.365M $5.966M
YoY Change 6.2% -62.56% 6.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.69M $15.13M $14.30M
Total Long-Term Liabilities $6.336M $6.365M $5.966M
Total Liabilities $29.77M $28.82M $29.27M
YoY Change 1.69% 3.77% -15.61%
SHAREHOLDERS EQUITY
Retained Earnings -$264.1M -$247.3M -$205.0M
YoY Change 28.84% 27.96%
Common Stock $357.2M $335.6M $271.1M
YoY Change 31.76% 16.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $95.77M $91.02M $68.72M
YoY Change
Total Liabilities & Shareholders Equity $125.5M $119.8M $97.99M
YoY Change 28.11% 10.5% -10.87%

Cashflow Statement

Concept 2012 Q4 2012 Q3 2011 Q4
OPERATING ACTIVITIES
Net Income -$16.81M -$15.03M -$12.73M
YoY Change 32.05% 27.7% -156.18%
Depreciation, Depletion And Amortization $720.0K $770.0K $840.0K
YoY Change -14.29% -36.89% -16.83%
Cash From Operating Activities -$13.32M -$10.95M -$9.370M
YoY Change 42.16% 35.86% 55.91%
INVESTING ACTIVITIES
Capital Expenditures -$110.0K -$70.00K -$110.0K
YoY Change 0.0% -41.67% -75.0%
Acquisitions
YoY Change
Other Investing Activities -$4.430M $6.060M $8.150M
YoY Change -154.36% -42.12% 2.52%
Cash From Investing Activities -$4.540M $5.990M $8.040M
YoY Change -156.47% -42.13% 7.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 19.57M 9.580M 120.0K
YoY Change 16208.33% -48000.0% -98.8%
NET CHANGE
Cash From Operating Activities -13.32M -10.95M -9.370M
Cash From Investing Activities -4.540M 5.990M 8.040M
Cash From Financing Activities 19.57M 9.580M 120.0K
Net Change In Cash 1.710M 4.620M -1.210M
YoY Change -241.32% 103.52% -110.56%
FREE CASH FLOW
Cash From Operating Activities -$13.32M -$10.95M -$9.370M
Capital Expenditures -$110.0K -$70.00K -$110.0K
Free Cash Flow -$13.21M -$10.88M -$9.260M
YoY Change 42.66% 37.03% 66.25%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
250000 USD
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-120000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-58000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-15000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
556000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-92000 USD
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
72000 USD
CY2011Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8594000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22615000 USD
CY2011Q3 us-gaap Royalty Expense
RoyaltyExpense
2318000 USD
us-gaap Royalty Expense
RoyaltyExpense
6761000 USD
CY2011Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2273000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6849000 USD
CY2011Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
656000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1622000 USD
us-gaap Costs And Expenses
CostsAndExpenses
37847000 USD
CY2011Q3 us-gaap Costs And Expenses
CostsAndExpenses
13841000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1703000 USD
CY2012Q3 us-gaap Costs And Expenses
CostsAndExpenses
17864000 USD
us-gaap Costs And Expenses
CostsAndExpenses
49082000 USD
CY2011Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11478000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-31016000 USD
CY2011Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
144000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
307000 USD
CY2011Q3 us-gaap Interest Expense
InterestExpense
438000 USD
us-gaap Interest Expense
InterestExpense
1358000 USD
CY2011Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11772000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-32067000 USD
CY2011Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.85
CY2011Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44136000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
56090000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37926000 shares
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
59467000 shares
CY2011Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-3000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-8000 USD
CY2011Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-117000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-89000 USD
CY2011Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11892000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32164000 USD
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14974000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42193000 USD
CY2012Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15027000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42316000 USD
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14751000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-41527000 USD
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.75
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21287000 USD
CY2011Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13097000 USD
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23187000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1696000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
96000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
121000 USD
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-5000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
58000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-26288000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
38353000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
48217000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
403000 USD
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
68000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-10199000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
62872000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
5000000 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
12503000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
28305000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-8000 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-8190000 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
11288000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
60185000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-12443000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-36456000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
35880000 USD
CY2012Q3 us-gaap Investments And Cash
InvestmentsAndCash
77600000 USD
CY2012Q3 cldx Working Capital
WorkingCapital
63700000 USD
CY2012Q3 us-gaap Secured Debt
SecuredDebt
12600000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4544137 shares
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1495000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5360999 shares
CY2011Q4 us-gaap Available For Sale Securities Debt Maturities Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost
41348000 USD
CY2011Q4 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
147000 USD
CY2011Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
219000 USD
CY2011Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
6136000 USD
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14298000 USD
CY2011Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
9008000 USD
CY2011Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5966000 USD
CY2011Q4 us-gaap Liabilities
Liabilities
29272000 USD
CY2012Q3 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
44000 USD
CY2011Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
271032000 USD
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2652000 USD
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-205006000 USD
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
68722000 USD
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
97994000 USD
CY2012Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
119837000 USD
CY2012Q3 us-gaap Stockholders Equity
StockholdersEquity
91015000 USD
us-gaap Basis Of Accounting
BasisOfAccounting
<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">(1)&#160; Basis of Presentation</font></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">&#160;</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The accompanying unaudited condensed consolidated financial statements have been prepared by Celldex Therapeutics,&#160;Inc. (the &#8220;Company&#8221; or &#8220;Celldex&#8221;) in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and reflect the operations of the Company and its wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">&#160;</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">These interim financial statements do not include all the information and footnotes required by U.S. GAAP for annual financial statements and should be read in conjunction with the audited financial statements for the year ended December&#160;31, 2011, which are included in the Company&#8217;s Annual Report on Form&#160;10-K filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;8, 2012.&#160; In the opinion of management, the interim financial statements reflect all normal recurring adjustments necessary to fairly state the Company&#8217;s financial position and results of operations for the interim periods presented.&#160; The year-end consolidated balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">&#160;</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for any future interim period or the fiscal year ending December&#160;31, 2012.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">&#160;</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">At September&#160;30, 2012, the Company had cash, cash equivalents and marketable securities of $77.6 million; working capital of $63.7&#160;million; and a Term Loan balance of $12.6&#160;million. The Company incurred a loss of $42.3&#160;million for the nine months ended September&#160;30, 2012.&#160; Net cash used in operations for the nine months ended September&#160;30, 2012 was $36.5&#160;million. The Company believes that the cash, cash equivalents and marketable securities at September&#160;30, 2012 will be sufficient to meet estimated working capital requirements and fund planned operations for at least the next twelve months.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">&#160;</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The Company raised net proceeds of $62.9 million during the nine months ended September&#160;30, 2012 from the issuance of its common stock.&#160; During the next twelve months, the Company may take further steps to raise additional capital to meet its long-term liquidity needs.&#160; These capital raising activities may include, but may not be limited to, one or more of the following: the licensing of technology programs with existing or new collaborative partners, possible business combinations, issuance of debt, or the issuance of common stock or other securities via private placements or public offerings. While the Company continues to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all, and the Company&#8217;s negotiating position in capital-raising efforts may worsen as existing resources are used. There is also no assurance that the Company will be able to enter into further collaborative relationships. Additional equity financing may be dilutive to the Company&#8217;s stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict the Company&#8217;s ability to operate as a business; and licensing or strategic collaborations may result in royalties or other terms which reduce the Company&#8217;s economic potential from products under development. If the Company is unable to raise the funds necessary to meet its long-term liquidity needs, it may have to delay or discontinue the development of one or more programs, discontinue or delay on-going or anticipated clinical trials, license out programs earlier than expected, raise funds at significant discount or on other unfavorable terms, if at all, or sell all or a part of the Company.</font></p></td></tr></table>
dei Entity Registrant Name
EntityRegistrantName
Celldex Therapeutics, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0000744218
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2012-09-30
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2012Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
61975120 shares
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2012Q3 cldx Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
27596000 USD
CY2012Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
24087000 USD
CY2012Q3 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
3 item
CY2011Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
435000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11899000 USD
CY2011Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
41413000 USD
CY2011Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
170000 USD
CY2011Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1202000 USD
CY2011Q4 us-gaap Assets Current
AssetsCurrent
54684000 USD
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9093000 USD
CY2011Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
24923000 USD
CY2011Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
329000 USD
CY2011Q4 us-gaap Goodwill
Goodwill
8965000 USD
CY2011Q4 us-gaap Assets
Assets
97994000 USD
CY2012Q3 us-gaap Goodwill
Goodwill
8965000 USD
CY2012Q3 us-gaap Assets Current
AssetsCurrent
78810000 USD
CY2012Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
54428000 USD
CY2012Q3 us-gaap Liabilities Current
LiabilitiesCurrent
15131000 USD
CY2012Q3 us-gaap Liabilities
Liabilities
28822000 USD
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
935000 USD
CY2011Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7008000 USD
CY2012Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
3000000 shares
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
3000000 shares
CY2012Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2011Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2011Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44210636 shares
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44210636 shares
CY2012Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60807350 shares
CY2012Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60807350 shares
CY2011Q3 cldx Revenue From Product Development And Licensing Agreements
RevenueFromProductDevelopmentAndLicensingAgreements
40000 USD
CY2011Q3 cldx Revenue From Contracts And Grants
RevenueFromContractsAndGrants
5000 USD
CY2011Q3 us-gaap Royalty Revenue
RoyaltyRevenue
2318000 USD
CY2011Q3 us-gaap Revenues
Revenues
2363000 USD
cldx Revenue From Product Development And Licensing Agreements
RevenueFromProductDevelopmentAndLicensingAgreements
65000 USD
cldx Revenue From Contracts And Grants
RevenueFromContractsAndGrants
5000 USD
us-gaap Royalty Revenue
RoyaltyRevenue
6761000 USD
us-gaap Revenues
Revenues
6831000 USD
CY2012Q3 us-gaap Revenues
Revenues
3113000 USD
us-gaap Revenues
Revenues
7555000 USD
CY2011Q4 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
82000 USD
CY2012Q3 us-gaap Available For Sale Securities Debt Maturities Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost
54242000 USD
CY2012Q3 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
194000 USD
CY2012Q3 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
8000 USD
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2011Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3325000 USD
CY2012Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3509000 USD
CY2011Q4 cldx Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
28248000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
836000 USD
CY2012Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
105000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
436000 USD
CY2012Q3 us-gaap Interest Expense
InterestExpense
381000 USD
CY2012Q3 us-gaap Deferred Rent Credit
DeferredRentCredit
434000 USD
CY2011Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
4661000 USD
CY2012Q3 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
4661000 USD
CY2011Q4 cldx Deferred Income From Sale Of Tax Benefits
DeferredIncomeFromSaleOfTaxBenefits
510000 USD
CY2012Q3 cldx Deferred Income From Sale Of Tax Benefits
DeferredIncomeFromSaleOfTaxBenefits
1118000 USD
CY2011Q1 cldx Deferred Income From Sale Of Tax Benefits
DeferredIncomeFromSaleOfTaxBenefits
500000 USD
CY2012Q1 cldx Deferred Income From Sale Of Tax Benefits
DeferredIncomeFromSaleOfTaxBenefits
700000 USD
CY2011Q4 us-gaap Loans Payable
LoansPayable
527000 USD
CY2012Q3 us-gaap Loans Payable
LoansPayable
486000 USD
CY2011Q4 us-gaap Other Sundry Liabilities
OtherSundryLiabilities
52000 USD
CY2012Q3 us-gaap Other Sundry Liabilities
OtherSundryLiabilities
65000 USD
CY2011Q4 us-gaap Other Liabilities
OtherLiabilities
6185000 USD
CY2012Q3 us-gaap Other Liabilities
OtherLiabilities
6764000 USD
CY2012Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
399000 USD
CY2012Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6365000 USD
CY2011Q1 cldx Value Of Tax Benefits Agreed To Be Sold
ValueOfTaxBenefitsAgreedToBeSold
600000 USD
CY2012Q1 cldx Value Of Tax Benefits Agreed To Be Sold
ValueOfTaxBenefitsAgreedToBeSold
800000 USD
cldx Period For Which Base Of Operations Must Be Maintained
PeriodForWhichBaseOfOperationsMustBeMaintained
P5Y
cldx Gain Loss On Sale Of Tax Benefits
GainLossOnSaleOfTaxBenefits
100000 USD
CY2012Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
12075000 shares
CY2012Q1 cldx Common Stock Exercise Of Full Over Allotment Option To Purchase Additional Shares By Underwriter
CommonStockExerciseOfFullOverAllotmentOptionToPurchaseAdditionalSharesByUnderwriter
1575000 shares
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
43400000 USD
CY2011Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
570000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1703000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1614000 USD
CY2012Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
525000 USD
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
7400000 shares
CY2012Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2011Q4 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2012Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
32000 USD
CY2012Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1163000 USD
CY2012Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7566000 USD
CY2012Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
409000 USD
CY2012Q3 us-gaap Assets
Assets
119837000 USD
CY2012Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1281000 USD
CY2012Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8157000 USD
CY2012Q3 us-gaap Secured Debt Current
SecuredDebtCurrent
5294000 USD
CY2012Q3 us-gaap Secured Long Term Debt
SecuredLongTermDebt
7326000 USD
CY2012Q3 us-gaap Common Stock Value
CommonStockValue
61000 USD
CY2012Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
335501000 USD
CY2012Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2775000 USD
CY2012Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-247322000 USD
CY2012Q3 cldx Revenue From Product Development And Licensing Agreements
RevenueFromProductDevelopmentAndLicensingAgreements
28000 USD
cldx Revenue From Product Development And Licensing Agreements
RevenueFromProductDevelopmentAndLicensingAgreements
103000 USD
CY2012Q3 cldx Revenue From Contracts And Grants
RevenueFromContractsAndGrants
79000 USD
cldx Revenue From Contracts And Grants
RevenueFromContractsAndGrants
228000 USD
CY2012Q3 us-gaap Royalty Revenue
RoyaltyRevenue
3006000 USD
us-gaap Royalty Revenue
RoyaltyRevenue
7224000 USD
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11769000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33650000 USD
CY2012Q3 us-gaap Royalty Expense
RoyaltyExpense
3006000 USD
us-gaap Royalty Expense
RoyaltyExpense
7224000 USD
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2835000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7372000 USD
CY2012Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
254000 USD
us-gaap Interest Expense
InterestExpense
1225000 USD
CY2012Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
2000 USD
CY2012Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
52000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1576000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
420000 USD
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
6000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
74000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1614000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
169000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
8000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
80000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
620000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
45432000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
57900000 USD
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-138000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
193000 USD
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
218000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
-2646000 USD
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
41000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
2000 USD
CY2012Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
297000000 shares

Files In Submission

Name View Source Status
0001104659-12-073441-index-headers.html Edgar Link pending
0001104659-12-073441-index.html Edgar Link pending
0001104659-12-073441.txt Edgar Link pending
0001104659-12-073441-xbrl.zip Edgar Link pending
a12-18753_110q.htm Edgar Link pending
a12-18753_1ex31d1.htm Edgar Link pending
a12-18753_1ex31d2.htm Edgar Link pending
a12-18753_1ex32d1.htm Edgar Link pending
cldx-20120930.xml Edgar Link completed
cldx-20120930.xsd Edgar Link pending
cldx-20120930_cal.xml Edgar Link unprocessable
cldx-20120930_def.xml Edgar Link unprocessable
cldx-20120930_lab.xml Edgar Link unprocessable
cldx-20120930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending